Oncologic efficacy of gonadotropin-releasing hormone agonist in hormone receptor-positive very young breast cancer patients treated with neoadjuvant chemotherapy

doi:10.12998/wjcc.v11.i27.6398

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 27

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2238)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

123

WORD

HTML

1062

Figures (1-3)

243

Tables (1-2)

247

Sum=1693

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

129

Download

323

Sum=452

Sep 26, 2023 (publication date) through Dec 19, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Cases. Sep 26, 2023; 11(27): 6398-6406
Published online Sep 26, 2023. doi: 10.12998/wjcc.v11.i27.6398

Open in New Tab Full Size Figure Download Figure

Figure 1 Algorithm of patient selection with strong hormone receptor-positive/ human epidermal grow factor 2-negative breast cancer. HR: Hormone receptor; HER2: Human epidermal grow factor 2.

Open in New Tab Full Size Figure Download Figure

Figure 2 Kaplan-Meier survival curves for disease free survival rates and overall survival rates between patients equal to or younger than 35 years and patients older than 35 years. A: Disease free survival rates; B: Overall survival rates.

Open in New Tab Full Size Figure Download Figure

Figure 3 Kaplan-Meier survival curves for disease free survival according to gonadotropin-releasing hormone agonist among younger than 35 years group. GnRH: Gonadotropin-releasing hormone.

Citation: Choi HJ, Lee JH, Jung CS, Ryu JM, Chae BJ, Lee SK, Yu JH, Kim SW, Nam SJ, Lee JE, Jung YJ, Kim HY. Oncologic efficacy of gonadotropin-releasing hormone agonist in hormone receptor-positive very young breast cancer patients treated with neoadjuvant chemotherapy. World J Clin Cases 2023; 11(27): 6398-6406
URL: https://www.wjgnet.com/2307-8960/full/v11/i27/6398.htm
DOI: https://dx.doi.org/10.12998/wjcc.v11.i27.6398